2006–07 · Dallas Mavericks
The upper-bowl cut and the $2 ticket
Writing on 11 December 2006, mid-way through a title-contending season with a running sellout streak, Cuban recorded that “we lowered the price of all tickets in our upper bowl and created a TWO DOLLAR ($2) ticket for 10 of our games”, with the stated theory that “lowering ticket prices is the most powerful, least expensive marketing we can do”. A post from 7 November 2006 corroborates it from the seats themselves.
Six months earlier he had declined to auction NBA Finals tickets: “If we were greedy, the Mavs would just put the tickets up for auction and take in the full value the market assigns to them.” An available rent, named as the greedy option, declined at the moment of maximum leverage.
Cuban's rolePrincipal owner. He set the schedule directly.
Structural?A price schedule, not a mechanism. Real, contemporaneous, and reversible by whoever owned the team next.
Price-setterManagerial practicePrimary source
2010 · Dallas Mavericks
A published low-price floor
The floor was not a one-season promotion. In September 2010 Cuban listed it publicly: “$2 for at least 10 games during the year. We have $5 singles for every game. We have 10 dollars seats for every game… We have more than 4k tickets priced under $20 for every game” — with best-available seats sold at the box office shortly before tip-off.
What makes this evidence rather than marketing is that the cheapest inventory is named, dated and quantified, and that it recurs: the floor is attested at dated points in 2006, 2010 and again in 2015. It is a floor, not a formula — the construction of the price was never shown to the fan.
Cuban's rolePrincipal owner. Price-setter on primary inventory.
Structural?Published and repeatable while he was in charge; never contractual.
Price-setterPublished floor
Feb 2014 · Dallas Mavericks
Price to fill, not to maximise
On 23 February 2014 Cuban described a full-time analyst continuously monitoring online pricing, and stated the rule: “It is far more important to know the price points that will enable you to fill the arena than to know the price points that will max out your total revenue.” The process, he wrote, “has resulted in us changing pricing for 7k season tickets for this coming year.”
The direction of that repricing is not stated in the post, and CHI does not infer it. What is not inferential is the rule itself: the reference point is the fan's outside option — the secondary market — rather than the revenue-maximising point. The same market-monitoring function was used by the team's later owners in the opposite direction, which is exactly why the tool cannot be read as a direction.
Cuban's rolePrincipal owner. He set the pricing process.
Structural?A pricing process, and direction-neutral as a tool. Supports as process only.
Price-setterProcess, not outcome
19 Jan 2022 · Cost Plus Drugs
Where instinct becomes architecture
This is the point at which a management preference becomes a mechanism. A public product page shows the acquisition cost, a fixed 15 per cent markup, $5.00 pharmacy labour and $5.25 standard shipping — visible before an account exists and before a prescriber is involved. An audit sample of 60 pages reconciled to the cent on all 60.
- Itemised margin disclosure — the company's own take is displayed, not just the price.
- Price before identity — no login, no insurance card, no eligibility check to see the number.
- Single-price logic — no coupon tier, no membership, no negotiated exception.
- Opt-in recurrence and zero-cost exit — no membership fee, self-service deletion.
The difference from the Mavericks is not sincerity. It is that this version is written into the product surface and is mathematically auditable by anyone.
Cuban's roleCo-founder and principal funder; the consumer price is the product.
Structural?Yes — a page template that binds the company on every product page.
Price-setterEngineered mechanism
2023 · Team Cuban Card
The template, re-used
The card programme republishes the same construction with a different schedule: the drug cost, a 15 per cent markup, a $12.00 fee and $1.00 — a published stack rather than a negotiated one. It is the first evidence that the Cost Plus page is a repeatable template rather than one product team's habit.
It also contains the clearest evidence that the transparency is a product decision rather than a corporate rule. The card's terms, dated 14 April 2023, put arbitration costs on “the claimant who initiates” — the inverse of the fee-advancement term in Cost Plus Drugs' own contract. Two affiliated entities drafted opposite terms within about eighteen months. Dispute clauses here look like counsel defaults, not founder policy.
Cuban's roleCo-founder; same corporate family.
Structural?Yes on price. No on contract — and the sibling inconsistency is itself a finding.
Price-setterIn-family repeat
2024–26 · Cost Plus Wellness
62 contracts at a zero fee
A public repository of direct employer–provider contracts, described by Cuban as “an open-source project, not a business”. The first contract is dated 22 November 2024; the public platform opened in January 2026; as of 6 September 2026 it publishes 62 provider contracts with no platform fee, no spread pricing, no shared-savings fee and no hidden administrative fee.
This is the strongest post-2022 parallel outside the pharmacy, and it is the one with the least to gain: there is no margin to align, because there is no margin. It is also, for that reason, untested by profit pressure — the FAQ notes “we may at some point charge for our services”.
Cuban's roleFounder and sponsor. Publishes the price; takes none of it.
Structural?Yes — and inside the same healthcare family as the other two.
Price-setterZero margin